Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III study of AJM300 in patients with active ulcerative colitis (2)

Trial Profile

Phase III study of AJM300 in patients with active ulcerative colitis (2)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs Carotegrast (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Sponsors EA Pharma; Kissei Pharmaceutical
  • Most Recent Events

    • 30 Jul 2018 Planned End Date changed from 1 Mar 2023 to 1 Dec 2020.
    • 12 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 06 Jun 2018 Planned initiation date changed from 1 May 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top